Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)

Active matrix metalloproteinase-8 and interleukin-6 detect periodontal degeneration caused by radiotherapy of head and neck cancer: a pilot study

Julkaisun tekijät: Keskin Mutlu, Lähteenmäki Hanna, Rathnayake Nilminie, Räisänen Ismo T., Tervahartiala Taina, Pärnänen Pirjo, Şenışık Ahmet Murat, Karaçetin Didem, Balkanay Ayben Yentek, Heikkilä Pia, Hagström Jaana, Rautava Jaana, Haglund Caj, Gursoy Ulvi Kahraman, Silbereisen Angelika, Bostanci Nagihan, Sorsa Timo

Kustantaja: Informa Healthcare

Julkaisuvuosi: 2020

Journal: Expert Review of Proteomics

Tietokannassa oleva lehden nimi: Expert review of proteomics

Lehden akronyymi: Expert Rev Proteomics

Volyymi: 17

Julkaisunumero: 10

Sivujen määrä: 8

ISSN: 1478-9450

eISSN: 1744-8387


Rinnakkaistallenteen osoite:


Background: This cohort study investigated the role of the active matrix metalloproteinase-8 (aMMP-8) and interleukin-6 (IL-6) as oral fluid biomarkers for monitoring the periodontal degeneration occurring in head and neck cancer (HNC) patients treated by radiotherapy.

Research design and methods: Eleven patients, aged 28-74, diagnosed with HNC were included in the study. Complete periodontal and oral examinations were performed pre-radiotherapy and 1 month after radiotherapy. Mouthrinse samples (pre-radiotherapy, after 6 weeks of radiotherapy and 1 month after radiotherapy) were assayed by aMMP-8 point-of-care-kit (PerioSafe®/ORALyzer®) for aMMP-8 and ELISA for IL-6.

Results: HNC radiotherapy had a deteriorating impact on the periodontium and a significant impact on periodontal biomarkers aMMP-8 and IL-6 and increased their levels in mouthrinse. Clinical-attachment-loss (CAL) (site of greatest loss: mean = 1.7 mm, range = 1-3 mm) corresponding to rapid progression of periodontitis. There was a positive repeated measures correlation (rmcorr = 0.667) between the aMMP-8 and IL-6 levels.

Conclusions: Elevated aMMP-8 levels were observed 1 month after radiotherapy among some HNC patients suggesting a prolonged increased susceptibility to further periodontal tissue destruction. Currently available aMMP-8 point-of-care testing could be useful to monitor and assess quantitatively online and real-time the risk of deterioration of periodontal health during HNC radiotherapy.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Last updated on 2022-07-04 at 18:16